Status:
RECRUITING
EffecTAVI Registry
Lead Sponsor:
Federico II University
Conditions:
Aortic Stenosis
Transcatheter Aortic Valve Replacement
Eligibility:
All Genders
55-100 years
Brief Summary
Aortic stenosis (AS) is the most common valvular heart disease among elderly population, with a increasing prevalence due to population ageing. In developed countries, the prevalence of severe AS amon...
Detailed Description
Aortic stenosis (AS) is the most common valvular heart disease among elderly population, with a increasing prevalence due to population ageing. In developed countries, the prevalence of severe AS amon...
Eligibility Criteria
Inclusion
- Patients with symptomatic severe AS or degenerated bioprosthetic aortic valve and suitable for TAVI according to Heart Team evaluation;
- Ability to provide informed consent.
Exclusion
- Contraindications to TAVI: e.g. evidence of intracardiac mass, thrombus or vegetation, endocarditis;
- Poor adherence to scheduled follow-up;
- Unable to understand and follow study-related instructions.
Key Trial Info
Start Date :
September 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05235555
Start Date
September 1 2015
End Date
January 1 2030
Last Update
February 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federico II University of Naples
Naples, Italy, 80131